EliLilly's operational performance is strong ... shares have seen downside of 14.8% at a time when the S&P500 is up 2.6%. The picture isn't as bad when we compare the data to my original ...
are used in diabetes and obesity drugs like EliLilly's Mounjaro and Zepbound. The stock (LLY) dropped 8.2% in morning trading, enough to make it the S&P500 index's SPX worst performer.